Royalty Pharma and Syndax Pharmaceuticals Strike $350M Royalty Deal for Niktimvo
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are…
BioNTech Reports Financial Results and Corporate Developments for Q3 2024
BioNTech SE (Nasdaq: BNTX) has announced its financial results for the third quarter and the first nine months of 2024, alongside updates on its corporate initiatives. During this period, the…
Legend Biotech Names Alan Bash as President of CARVYKTI
Legend Biotech Corporation (NASDAQ: LEGN), a global leader in cell therapy, has announced the appointment of Alan Bash as the President of CARVYKTI®. In this newly established position, Mr. Bash…
Neurocrine Biosciences Reveals INGREZZA® Data: Most Achieve Tardive Dyskinesia Remission
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased findings from the long-term KINECT®-4 study, revealing that nearly 60% of participants achieved remission from tardive dyskinesia after 48 weeks of treatment with once-daily…
Arrowhead Pharmaceuticals Launches We’ll Get There Soon Campaign for Familial Chylomicronemia Syndrome Awareness
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the launch of a new disease awareness campaign titled “We’ll Get There Soon” on FCS Awareness Day. The initiative aims to raise awareness…
Neurocrine Biosciences Shows Long-Term Benefits of INGREZZA® for Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) recently presented data from over 300 patients with tardive dyskinesia treated with INGREZZA® (valbenazine) capsules, revealing significant improvements in functional, social, emotional, and health-related quality…
Ionis Announces FDA Review of Donidalorsen NDA for Preventive Treatment of HAE
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted therapy for preventing hereditary…
WHO Study Identifies Key Endemic Pathogens in Urgent Need of New Vaccines
A recent World Health Organization (WHO) study, published in eBioMedicine, has identified 17 priority pathogens that are endemic in various communities and urgently require new vaccines. This marks WHO’s first…
Libra Therapeutics Names Dr. Shawn A. Scranton as President and CEO
Libra Therapeutics, Inc., a private biotechnology company focused on developing innovative therapies to restore cellular balance and reduce neurodegeneration, has announced the appointment of Shawn A. Scranton, PharmD, as President…
Kashiv BioSciences Names Dr. Sandeep Nilkanth Athalye as Global CEO
Kashiv BioSciences, LLC, a globally integrated biopharmaceutical company, has appointed Dr. Sandeep Nilkanth Athalye as its new Global Chief Executive Officer. With over 20 years of experience in strategic and…
Medidata and Cogstate Partner to Enhance Neurology Clinical Trials with AI Solutions
Medidata, a brand of Dassault Systèmes and a leading provider of clinical trial solutions, has partnered with Cogstate, a leader in neuroscience solutions, to transform clinical trials and outcome measurements…
Vir Biotechnology Releases Q3 2024 Financial Results and Corporate Update
Vir Biotechnology, Inc. (Nasdaq: VIR) has released its corporate update and financial results for the third quarter ended September 30, 2024. “This quarter marked a transformative period for Vir. We…